background preloader

Pharmaceutical Medicine - Pharmacovigilance

Facebook Twitter

Communicating about Risks and Safe Use of Medicines - Real Life and Applied Research. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID‐19 (SARS‐COV‐2) treatments - Baker - - British Journal of Clinical Pharmacology - Wiley Online Library. Safety Data and Withdrawal of Hepatotoxic Drugs - PubMed. Background and aim: The occurrence of drug induced liver injury (DILI) is the most common reason of post-marketing withdrawals.

Safety Data and Withdrawal of Hepatotoxic Drugs - PubMed

DILI in humans is difficult to predict using in vitro cytotoxicity screening and animal studies. A review of hepatotoxicity data was performed with the aim of identifying relevant factors that could have predicted the occurrence of serious DILI. Methods: The drugs withdrawn from the market due to hepatotoxicity in Europe and/or in USA either by marketing authorization holders or by Regulatory agencies from 1997 to 2016 were selected. The liver safety data and the withdrawal decisions were identified from a search within the European medicine agency (EMA) website, the Food and drug administration (FDA) orange book and PubMed®. Results: From 1997 to 2016, eight drugs were withdrawn from the market for hepatotoxicity reason: tolcapone, troglitazone, trovafloxacin, bromfenac, nefazodone, ximelagatran, lumiracoxib and sitaxentan. Drug Recall: An Incubus for Pharmaceutical Companies and Most Serious Drug Recall of History - PubMed.

There has been an increasing trend in the number of prescribed and over-the-counter drug recall over the last few years.

Drug Recall: An Incubus for Pharmaceutical Companies and Most Serious Drug Recall of History - PubMed

The recall is usually due to company's discovery, customer's complaint or Food and Drug Administration (FDA) observation. The process of recall involves a planned specific course of action, which addresses the depth of recall, need for public warning, and the extent of effectiveness checks for the recall. The FDA review and/or recommend changes to the firm's recall strategy, as appropriate. The critical recall information list includes the identity of the product; summary of the failure; amount of product produced in the distribution chain and direct account. Medical Device Recalls and the FDA Approval Process - PubMed. Background: Unlike prescription drugs, medical devices are reviewed by the US Food and Drug Administration (FDA) using 2 alternative regulatory standards: (1) premarket approval (PMA), which requires clinical testing and inspections; or (2) the 510(k) process, which requires that the device be similar to a device already marketed (predicate device).

Medical Device Recalls and the FDA Approval Process - PubMed

The second standard is intended for devices that the FDA deems to involve low or moderate risk. Methods: We analyzed the FDA's high-risk List of Device Recalls from 2005 through 2009. Using FDA data, we determined whether the recalled devices were approved by the more rigorous (PMA) process, the 510(k) process, or were exempt from FDA review.

Results: There were 113 recalls from 2005 through 2009 that the FDA determined could cause serious health problems or death. Only 21 of the 113 devices had been approved through the PMA process (19%). Characteristics of FDA Drug Recalls: A 30-month Analysis - PubMed. Purpose: The characteristics of drug recalls issued over 30 months by the Food and Drug Administration (FDA) were analyzed.

Characteristics of FDA Drug Recalls: A 30-month Analysis - PubMed

Methods: All FDA-issued recalls for drugs (prescription and nonprescription, including dietary supplements) and biological products issued from June 20, 2012, to December 31, 2014, were included in this retrospective analysis. Data for all drug recalls were downloaded and sorted by the inclusion criteria from weekly FDA enforcement reports. The following data were analyzed: product type, recall firm, type of recall firm (compounding or noncompounding), country, voluntary or involuntary recall, method of communication of recall, recall number, FDA recall classification (class I, II, or III), product availability (prescription or nonprescription), reason for recall, recall initiation date, and recall report date.

Results: A total of 21,120 products were recalled during the 30-month study period. Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. Notwithstanding successful harmonization efforts, the global regulatory framework governing product safety is complex and continually evolving, as evidenced by additional regional guidance and regulations.

Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions

In this regulatory review, we provide an overview from both global and regional perspectives. A historical perspective, with a focus on recent developments, enables identification of important long–term trends, such as a shift from single–case medical review of serious adverse events to an interdisciplinary evaluation of aggregate data for the purpose of judging product causality and informing benefit–risk assessments. We will show how these trends lead to opportunities for closer interdisciplinary collaboration, for bridging the gap between preand postmarketing surveillance, and for a more proactive determination of patient populations with a positive benefit–risk profile for product use.

Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future. An examination for potential direct or indirect adverse effects on the immune system (immunotoxicity) is an established component of nonclinical testing to support safe use of new drugs.

Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future

Testing recommendations occur in various regulatory guidance documents, especially ICH S8, and these will be presented. Key evaluation usually occurs in toxicology studies with further investigative work a consideration if a positive signal is seen. Expectations around whether findings may occur are related to the type of compound being developed, including a chemically synthesized small molecule, a small molecule oncology drug, a biopharmaceutical, an oligonucleotide, a gene therapy/stem cell product, a vaccine, or reformulation of drugs in liposomes or depots.

Adverse Drug Reaction Relief System in Japan: From Clinical Perspective. Adverse drug reaction (ADR) relief system in Japan is comprehensively described in this article.

Adverse Drug Reaction Relief System in Japan: From Clinical Perspective

Particularly, review process during ADR relief evaluation is focused from clinical perspective. Use of “Big Data” to Evaluate Responses to Changes in Regulatory Guidelines: Trends in Genotoxicity Testing Packages for New Pharmaceutical Products. Background In 2006, a concept paper (ICH S2(R1)) describing the need for revision of the ICH guidelines on genotoxicity testing for new “small molecule” pharmaceuticals (then ICH S2A and ICH S2B) was finalised.

Use of “Big Data” to Evaluate Responses to Changes in Regulatory Guidelines: Trends in Genotoxicity Testing Packages for New Pharmaceutical Products

As a result, testing strategy has changed, and flexibility has been introduced in the form of two “equally suitable” options for completing the battery of genotoxicity studies required to support clinical development and marketing of new products. Methods The TIBCO Spotfire® platform was used to create a specific view of available in-house data on genotoxicity studies conducted to support pharmaceutical product development over a period of approximately 12 years. A Framework for Safety Evaluation Throughout the Product Development Life-Cycle. From Print to Screen: Regulatory Considerations to Adopting Innovative Approaches for Patient Information and Safety. Promote a Digital Outlook and Act for Change We believe that strong political commitment at the highest level is important in ensuring that society accepts the use of and transition to digital platforms.

From Print to Screen: Regulatory Considerations to Adopting Innovative Approaches for Patient Information and Safety

A clear endorsement and support to achieve this can help overcome administrative resistance and safeguard it from singular interests. For example, some international organizations and countries have developed clear guidelines and strategies that reflect their future outlook with regard to digital platforms (Box 1). Review and Streamline Regular review is necessary to ensure that regulations are suited to the current technological developments; encourage innovation; and, more importantly, ensure that safe, efficacious, and quality medicinal products are received by the patients in a timely manner (Box 2).

Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities. s43441 020 00158 8. {b3981236 3b16 4732 ab91 f9bc545aa09e} The Future of Safety. IUPHAR Guide to IMMUNOPHARMACOLOGY. IUPHAR/BPS Guide to PHARMACOLOGY. Medicine Shortages: Gaps Between Countries and Global Perspectives. Introduction The World Health Organization (WHO) defined “access to medicines” as a multidimensional problem in view of the rising prices of new medicines and persisting problems of medicine shortages among others (World Health Organization, 2018).

Medicine Shortages: Gaps Between Countries and Global Perspectives

Detecting Adverse Drug Events: Accuracy and Generalizability - Scott R. Walter, Blanca Gallego, 2019. Pharmacovigilance 2030 - Arlett - - Clinical Pharmacology & Therapeutics - Wiley Online Library. A new healthcare system is emerging that encompasses systems approaches to biology and medicine, radically enhanced capabilities for collecting, integrating, storing, analyzing, and communicating data and information, and increasing numbers of networked and activated patients and consumers. Pharmacovigilance systems around the world have come a long way in the last 60 years. Systems have evolved from reliance on the individual case safety report (ICSR) of suspected adverse drug reactions (ADRs), through addition of the periodic safety update report, and risk management plan, to the current era where many stringent regulators have a pallet of regulatory tools and access to an ever increasing spectrum of data sources, real‐world or otherwise.

Modern systems also leverage the collaborative efforts of multiple stakeholders, notably the biopharmaceutical industry, regulators, healthcare professionals, patients, and academia. A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms. Acknowledgements The authors thank Prof. Stephen Evans (London School of Hygiene and Tropical Medicine) and Mr. Sten Olsson (Uppsala Monitoring Centre, the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden) for providing comments and feedback to the questionnaire, and Betty Chan for assisting in collation of the results. We would like to acknowledge Dr.

A Pharmacoepidemiology Database System for Monitoring Risk Due to the Use of Medicines by New Zealand Primary Care Patients - PubMed. Introduction: The use of large record-linked healthcare databases for drug safety research and surveillance is now accepted practice. New Zealand's standardized national healthcare datasets provide the potential to automate the conduct of pharmacoepidemiological studies to provide rapid validation of medicine safety signals. Objectives: Our objectives were to describe the methodology undertaken by a semi-automated computer system developed to rapidly assess risk due to drug exposure in New Zealand's population of primary care patients and to compare results from three studies with previously published findings. Methods: Data from three national databases were linked at the patient level in the automated studies.

Results: The patient cohort available for each study included 5,194,256 patients registered between 2007 and 2014, with a total of 34,630,673 patient-years at risk. Causality Assessment in Pharmacovigilance: Still a Challenge - PubMed. Causality in pharmacovigilance is a difficult and time consuming exercise. This paper presents the challenges in determining causation by drug therapy. The first is that causation is complex and needs to be viewed from the context of the patient treated, rather than the drug product. Multiple causal vectors should be considered if we are to tackle the many issues involved in, for example, medication error and the many other factors that lead to bad outcomes from therapy, including failure to recognise known risk factors.

Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. Active Surveillance of Follow-on Biologics: A Prescription for Uptake. Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification. Patient Reporting in the EU: Analysis of EudraVigilance Data.

Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals. Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study. Global Health & Pharma - Breaking Down Data Silos to Improve Pharmacovigilance. According to Harvard University’s Edmond J. Safra Center for Ethics, up to 200,000 deaths per year in Europe are attributed to adverse drug reactions.

This puts a strong emphasis on the need for more effective drug safety precautions and processes – pharmacovigilance – with an aim of safer medicines for everyone. This is not a new concept, but with the multitude of modern health data sources, both the task and opportunity become more complex. Detecting adverse events arising from patients’ use of medicines in the real world can be done better than ever before, but it’s tougher than it sounds.

Medicine Safety - Pharmaceutical Society of Australia. A72 29 en. A72 26 en. REMS Safety Information. FDA Issues Draft Guidance Regarding Waiver of Single Shared System REMS Requirement. Printer-Friendly Version FDA Commissioner Scott Gottlieb has vowed to take steps to speed the review and approval of generic drugs as part of his overall priority to address concerns about drug prices. While FDA has very limited authority regarding drug pricing, Commissioner Gottlieb has pushed to encourage generic competition and has sought to address regulatory issues that he believes could be impediments to that competition. Pharmacovigilance: An Overview - Clinical Therapeutics. Thus, 3 core functions of PV exist: case management, signal management, and benefit–risk management.

To understand how these activities are related to one another, however, it is helpful to look at them from a systems perspective (Figure 1Figure 1). Figure 1. IDMP Standards - Identification of Medicinal Products. Social media and pharmacovigilance: A review of the opportunities and challenges. Main Page. R effect table rapporteurship chmp discussion epar andreas kouroumalis en. PROTECT Benefit-Risk. Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Chronopharmacokinetics of drugs in toxicological aspects: A short review for pharmacy practitioners.

Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. NPR Choice page. Researchers question design of fatal French clinical trial. Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020. Pharmacovigilance of Oncology Biosimilars. Pharmacovigilance of biosimilars: challenges and possible s - GaBI Journal. Keywords: biologicals, biosimilars, immunogenicity, pharmacovigilance, traceability Author byline as per print journal: Thijs J Giezen, PharmD, PhD; Sabine MJM Straus, MD, PhD. Utilizing social media data for pharmacovigilance: A review. JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page. Nihms 148619. Lack of monitoring adverse drug reactions in developing countries. Rob10069 fm. Consumer Narratives in ADR Reporting: An Important Aspect of Public Health? Experiences from Reports to a Swedish Consumer Organization.

The Calculus of Cures. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. Question Are characteristics of novel therapeutics known at the time of US Food and Drug Administration (FDA) approval associated with postmarket safety events, including withdrawal, boxed warnings, and safety communications? Findings Among 222 novel therapeutics approved by the FDA from 2001 through 2010, 71 (32.0%) were affected by a postmarket safety event. Postmarket safety events were more frequent among biologics, therapeutics indicated for the treatment of psychiatric disease, those receiving accelerated approval, and those with near–regulatory deadline approval. Pharmacovigilance - Monitoring of medical literature and entry of adverse reaction reports into EudraVigilance.

The European Medicines Agency (EMA) is responsible for monitoring a number of substances and selected medical literature to identify suspected adverse reactions with medicines authorised in the European Union, and for entering the relevant information into the EudraVigilance database. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization. - PubMed - NCBI.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). - PubMed - NCBI. Social media and networks in pharmacovigilance: boon or bane? - PubMed - NCBI. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. - PubMed - NCBI. Pharmacovigilance activities in ASEAN countries. - PubMed - NCBI. Preclinical research in drug development. Juvenile Animal Testing: Assessing Need and Use in the Drug Product Label - Paul Baldrick, 2018.

Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans. - PubMed - NCBI. The Exciting Future of Pharmacovigilance. Machine Learning in Pharmacovigilance. Gaz10250 fm. Pharmacology Education Project. International Coalition of Medicines Regulatory Authorities (ICMRA) Database Access - UNSW Library. Educational Infographic produced by the Human Toxicology Project Consortium – Human Toxicology Project Consortium. A new infographic produced by the Human Toxicology Project Consortium shows in three sections how the future of toxicity testing promises a steady reduction in testing costs, increases in human relevance and confidence in safety assessments, and the eventual elimination of animal tests.

The first section provides a snapshot comparison of the current and future costs, efficiency and efficacy of toxicity testing, while the mid portion uses pesticide testing as a specific example of now, vs near-future, vs the optimal approach that, given the focus and resources necessary, will be envisioned within the decade. The Fate of FDA Postapproval Studies. FDA unveils searchable adverse events system. Would you like to trial the new design? Try it out now. 6275 1600 coding basics. Pharmacovigilance and risk link. IUPHAR/BPS Guide to PHARMACOLOGY. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.

The Future of Pharmacovigilance: Proposals for More Efficient and Effective Systems-Based Approaches. 9789241508254 eng. Prepare for the Unexpected - Feature. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Database Access - UNSW Library. Pharmacogenomic Associations Tables. Expedited Approval Without Expedited Follow-up. New Drugs Approved by the US FDA in 2008. Gastrointestinal Bleeding With Dabigatran. Gathering Safety Information About Medications. IMEDS. Pharmacovigilance DDI Webinar 03022017. Overall Survival for Patient-Reported Symptom Monitoring in Routine Cancer Treatment. Merck KGaA's oral multiple sclerosis therapy Mavenclad gains support from EU panel - FirstWord Pharma.

Green light given for new EudraVigilance system for collection and monitoring of suspected adverse reactions. EudraVigilance - EudraVigilance system overview. Jamanetwork. Imdrf tech 170316 aer n43.